Law Offices of Todd M. Garber Announces Investigation of Vanda
LOS ANGELES -- July 3, 2013
The Law Offices of Todd M. Garber announces that it is investigating potential
claims against Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”)
(NASDAQ:VNDA) concerning possible violations of federal securities laws. The
investigation focuses on certain statements issued by Vanda between December
18, 2012 and June 18, 2013 regarding the Company’s business and financial
Vanda is a biopharmaceutical company engaged in the development and
commercialization of products for the treatment of central nervous system
disorders. The Company’s product tasimelteon -- a treatment for circadian
rhythm sleep disorders (CRSD) -- is currently in clinical development for a
serious, rare CRSD known as “Non-24.” The investigation concerns allegations
that the Company issued false and misleading statements or failed to disclose
material adverse facts concerning the Phase III clinical trials for
tasimelteon, including (1) whether the primary endpoint installed to assess
tasimelteon’s efficacy and safety was replaced by the Company with an endpoint
that was not endorsed by the Food and Drug Administration and had never been
used before in sleep-drug clinical trials, and (2) whether tasimelteon
demonstrated any discernible difference in efficacy and safety in nighttime
total sleep between those patients deemed to have Non-24 and those patients
with a normal circadian rhythm.
If you purchased Vanda stock during the foregoing period, if you have
information or would like to learn more about these claims, or if you
purchased Vanda shares prior to December 18, 2012 and wish to discuss these
matters, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M.
Garber, by telephone at 213-700-7262 or by email to firstname.lastname@example.org.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
The Law Offices of Todd M. Garber
Todd M. Garber, Attorney at Law
Press spacebar to pause and continue. Press esc to stop.